"Pancreatic cancer is not one disease, but many, and suggests that people who seemingly have the same cancer might need to be treated differently" said Professor Andrew Biankin as he discussed the APGI's findings published in Nature. This is set to change the face of treatment, moving towards the vision of personalised medicine which matches the right treatment to the right individual.
APGI researchers at the Garvan Institute were awarded the Cancer Institute NSW Inaugural Wildfire Award 2012. This prestigious award recognises research which has had a lasting impact on the cancer field.
November is International Pancreatic Cancer Awareness Month. Please join us in raising much needed awareness for this devastating disease. You can participate in one of our scheduled events, arrange your own or simply make a donation. Everything helps!
The APGI contributed to this study and co-authors this Nature Publication. We’re now seeing some real movement in the field of pancreatic cancer research, and the APGI has been at the heart of much of this work.
Sean Grimmond presents at sequencing seminar during Advances in Genome Biology and Technology Meeting.
There is a need to to develop biological markers (biomarkers) to better group pancreatic cancer sufferers for treatment types and for testing individual treatment strategies. A Sydney gastroenterologist, Dr Humphris who is part of the APGI research team has brought new insight to this battle with his work on CA19.9.